MOBERG DERMA SIGNS AGREEMENT FOR EMTRIX® IN PORTUGAL AND 10 MARKETS IN AFRICA AND CENTRAL AMERICA.

Moberg Derma AB today announced that a distribution agreement has been entered into with Laboratorio EDOL Produtos Farmaceuticos S.A. for Emtrix® – Moberg Derma’s product for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement EDOL is granted exclusive rights to market and sell Emtrix® in Portugal and ten markets in Africa and Central America. Moberg Derma will manufacture Emtrix® for EDOL.

"The agreement with EDOL enables Emtrix® to be promoted on additional geographic markets, and contributes to our strategy to develop Emtrix® into a global product. We look forward to the collaboration with EDOL," comments Moberg Derma's CEO, Peter Wolpert. 

About Emtrix® and nail diseases
Emtrix® is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix® was initiated in the first markets in September 2010. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

Contact Moberg Derma
Peter Wolpert, CEO
Mob.:                   +46 (0)70-735 71 35
E-mail:                peter.wolpert@mobergderma.se

About Moberg Derma
Moberg Derma AB, Stockholm, develops and commercialises patented medical products for topical treatment, focusing on skin diseases. The company develops innovative products based on proven substances. Moberg Derma licences product rights to partners and distributors, whilst at the same time retaining certain marketing rights. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, and by the company management. For further information, please visit: www.mobergderma.se 

About EDOL
EDOL Produtos Farmaceuticos S.A is a leading Portuguese pharmaceutical company that develops, manufactures and sells products for skin and eye diseases and diseases related to the ears, nose and throat. The company's main markets are Portugal, Angola, Benin, the Dominican Republic, the Ivory Coast, El Salvador, Ethiopia, Cape Verde, Mozambique, Morocco and Togo. For further information, please visit www.edol.pt

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro® and Fiber Choice®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe

Documents & Links